Dapagliflozin After Transcatheter Aortic Valve Implantation According to Frailty in DapaTAVI Trial.

What was studied

This was a further analysis of the DapaTAVI trial. The trial gave dapagliflozin to patients after a heart valve procedure. The procedure was a transcatheter aortic valve implant for severe aortic stenosis. The team asked if the drug works differently by frailty. Frailty was scored on a scale. Patients were robust, prefrail, or frail. The main outcome was death from any cause or worse heart failure at 1 year.

What they found

The analysis had 1222 patients with a frailty score. Over 12 months, 215 patients had the main outcome. Prefrail and frail patients had a higher risk than robust patients. Dapagliflozin was linked to a lower risk in frail patients. It was not linked to a lower risk in prefrail or robust patients. The test for a difference by frailty was significant. There was no evidence that frailty changed the drug safety profile.

What it means for patients

The authors say frailty was common after the procedure. They link it to worse outcomes. They say dapagliflozin appeared to give a greater relative benefit in frail patients.

Why it is not certain yet

This was a post hoc analysis of a trial. Patients were not assigned by chance to frailty groups. Estimates for robust patients were wide. The abstract says the drug appeared to help more, not that it proved it. The abstract does not give how large the absolute gain was.

Source

Dapagliflozin After Transcatheter Aortic Valve Implantation According to Frailty in DapaTAVI Trial.

We restate facts from the source record in our own words. The original wording belongs to its publisher.